Sevenfact Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in recombinant clotting factor development, improved survival rates in hemophilia patients, expansion of specialized hemophilia treatment centers, availability of targeted bleeding management protocols, increased awareness of inhibitor complications.

The growth in the forecast period can be attributed to increasing adoption of personalized hemophilia therapies, rising demand for safer recombinant products, expansion of home-based bleeding management, growing focus on prophylactic treatment strategies, innovation in next-generation coagulation agents. Major trends in the forecast period include increasing adoption of recombinant coagulation factors, rising focus on inhibitor hemophilia management, growing demand for on-demand bleeding control therapies, expansion of precision hemostasis treatments, enhanced focus on rapid-acting clotting agents.

The increasing prevalence of blood disorders is expected to drive the growth of the sevenfact market going forward. Blood disorders are conditions that affect the components or functions of blood, including red blood cells, white blood cells, platelets, or plasma. The rise in blood disorders is influenced by factors such as an aging population, genetic predispositions, chronic illnesses, and infections or inflammatory conditions. Sevenfact supports patients with blood disorders by promoting effective blood clotting in individuals with hemophilia A or B with inhibitors, helping to control bleeding episodes and reduce the risk of serious complications. For instance, in April 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, there were 2.8 million visits to physician offices for anemia as the primary diagnosis, with 6,021 deaths, resulting in a mortality rate of 1.8 deaths per 100,000 population. Therefore, the increasing prevalence of blood disorders is driving the growth of the sevenfact market.

The rising government healthcare spending is expected to propel the growth of the sevenfact market going forward. Government healthcare spending refers to the allocation of public funds to support healthcare services, programs, and infrastructure for citizens. The increase in government healthcare spending is driven by factors such as an aging population, rising prevalence of chronic conditions, advancements in medical technology, and the need for improved healthcare infrastructure and services. Sevenfact can help manage rising healthcare expenditures by providing a cost-effective treatment for hemophilia patients with inhibitors, potentially reducing long-term costs associated with frequent hospitalizations and emergency care while improving patient outcomes and quality of life. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health expenditure was projected to reach $344 billion in 2023, reflecting a 2.8% increase compared to the previous year. Therefore, the rising government healthcare spending is driving the growth of the sevenfact market.

Major companies operating in the sevenfact market are focusing on technological advancements, such as recombinant protein formulation optimization, to gain a competitive edge. This technology involves modifying the protein composition of coagulation factor VIIa to create multiple dosage strengths that enhance dosing flexibility, simplify administration, and improve patient adherence. For instance, in June 2024, LFB S.A., a France-based biopharmaceutical company, launched a new 2 mg dosage strength of SEVENFACT (coagulation factor VIIa, recombinant-jncw). This launch includes a co-packaged 3 mL prefilled sterile water syringe for easier reconstitution, enables precise dosing for moderate bleeds, and reduces the number of vials required per administration. These improvements enhance convenience for patients and healthcare providers while supporting efficient prescription delivery and inventory management.

Major companies operating in the sevenfact market are HEMA Biologics Inc.

North America was the largest region in the sevenfact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sevenfact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sevenfact market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the sevenfact market by increasing costs of imported recombinant protein manufacturing equipment, cell culture media, purification resins, and sterile injectables packaging components. North America and Europe face the greatest impact due to dependence on global biologics supply chains, while emerging markets encounter higher access costs. These tariffs elevate production expenses and affect treatment affordability. However, they are also supporting regional biologics manufacturing, localized fill-finish operations, and long-term investments in domestic coagulation factor production capabilities.

The sevenfact market research report is one of a series of new reports that provides sevenfact market statistics, including sevenfact industry global market size, regional shares, competitors with a sevenfact market share, detailed sevenfact market segments, market trends and opportunities, and any further data you may need to thrive in the sevenfact industry. This sevenfact market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sevenfact is a recombinant coagulation factor VIIa (eptacog beta) used to treat and control bleeding episodes in patients with hemophilia A or B who have inhibitors. It works by promoting blood clot formation to manage bleeding.

The primary indications for Sevenfact are hemophilia A and hemophilia B. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, resulting in impaired blood clotting and frequent bleeding episodes. The product is distributed through hospital and specialty pharmacies, and its end-use settings include hospitals, clinics, ambulatory care, and home care.

The sevenfact market consists of sales of sevenfact injections, sevenfact lyophilized powder, and sevenfact prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.